Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
To read the full story
Related Article
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
- Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
May 13, 2022
- JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
- Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
ORGANIZATION
- JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
- Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
April 18, 2024
- Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
April 10, 2024
- JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
- New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
April 8, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…